Comparison of Sequential Intravesical Gemcitabine and Docetaxel vs Bacillus Calmette-Guérin for the Treatment of Patients With High-Risk Non–Muscle-Invasive Bladder Cancer

IMPORTANCE: Due to the ongoing bacillus Calmette-Guérin (BCG) shortage, sequential intravesical gemcitabine and docetaxel has been increasingly used as first-line therapy for high-risk non–muscle-invasive bladder cancer (NMIBC). However, data directly comparing these 2 therapies are lacking. OBJECTI...

Descripción completa

Detalles Bibliográficos
Autores principales: McElree, Ian M., Steinberg, Ryan L., Mott, Sarah L., O’Donnell, Michael A., Packiam, Vignesh T.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Medical Association 2023
Materias:
Original Investigation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9975907/
https://www.ncbi.nlm.nih.gov/pubmed/36853609
http://dx.doi.org/10.1001/jamanetworkopen.2023.0849

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9975907/
https://www.ncbi.nlm.nih.gov/pubmed/36853609
http://dx.doi.org/10.1001/jamanetworkopen.2023.0849

Ejemplares similares